-+ 0.00%
-+ 0.00%
-+ 0.00%

Guggenheim Maintains Buy on Merck & Co, Raises Price Target to $171

Benzinga·10/30/2026 13:13:06
Guggenheim analyst Vamil Divan maintains Merck & Co (NYSE:MRK) with a Buy and raises the price target from $170 to $171.